The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 26, 2024
Filed:
Sep. 14, 2023
Applicant:
Modernatx, Inc., Cambridge, MA (US);
Inventors:
Kerry E. Benenato, Cambridge, MA (US);
Mark Cornebise, Cambridge, MA (US);
Ellalahewage Sathyajith Kumarasinghe, Cambridge, MA (US);
Assignee:
ModernaTX, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 229/12 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/16 (2006.01); A61K 9/51 (2006.01); A61K 31/7105 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01); A61K 48/00 (2006.01); C07C 227/16 (2006.01); C07C 227/18 (2006.01); C07C 229/16 (2006.01); C07C 233/36 (2006.01); C07C 233/72 (2006.01); C07C 235/10 (2006.01); C07C 255/24 (2006.01); C07C 263/20 (2006.01); C07C 271/20 (2006.01); C07C 275/14 (2006.01); C07C 279/12 (2006.01); C07C 279/24 (2006.01); C07C 279/28 (2006.01); C07C 279/32 (2006.01); C07C 311/05 (2006.01); C07C 335/08 (2006.01); C07D 207/27 (2006.01); C07D 233/72 (2006.01); C07D 249/04 (2006.01); C07D 263/20 (2006.01); C07D 265/33 (2006.01); C07D 271/06 (2006.01); C07D 271/10 (2006.01); C07D 277/38 (2006.01); C07F 9/09 (2006.01); C07K 14/505 (2006.01);
U.S. Cl.
CPC ...
C07C 229/12 (2013.01); A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0073 (2013.01); A61K 9/127 (2013.01); A61K 9/1272 (2013.01); A61K 9/1617 (2013.01); A61K 9/1641 (2013.01); A61K 9/5123 (2013.01); A61K 9/5146 (2013.01); A61K 31/7105 (2013.01); A61K 38/1725 (2013.01); A61K 38/1816 (2013.01); A61K 47/543 (2017.08); A61K 47/6911 (2017.08); A61K 48/0033 (2013.01); A61K 48/005 (2013.01); C07C 227/16 (2013.01); C07C 227/18 (2013.01); C07C 229/16 (2013.01); C07C 233/36 (2013.01); C07C 233/72 (2013.01); C07C 235/10 (2013.01); C07C 255/24 (2013.01); C07C 263/20 (2013.01); C07C 271/20 (2013.01); C07C 275/14 (2013.01); C07C 279/12 (2013.01); C07C 279/24 (2013.01); C07C 279/28 (2013.01); C07C 279/32 (2013.01); C07C 311/05 (2013.01); C07C 335/08 (2013.01); C07D 207/27 (2013.01); C07D 233/72 (2013.01); C07D 249/04 (2013.01); C07D 263/20 (2013.01); C07D 265/33 (2013.01); C07D 271/06 (2013.01); C07D 271/10 (2013.01); C07D 277/38 (2013.01); C07F 9/091 (2013.01); C07K 14/505 (2013.01); A61K 9/1271 (2013.01); A61K 48/00 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/14 (2017.05); C07C 2601/18 (2017.05);
Abstract
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.